IMS 2026 | Age Gauge platform: improving older-adult representation in myeloma trials

At Ohio State, we recognize that many patients who come from clinical trials come from all over the state of Ohio, come from rural areas, from non-metropolitan areas and metropolitan areas as well. And one of the ways that we wanted to be able to better identify who was enrolling into our clinical trials was the creation of a real-time online platform that any of the physicians or principal investigators can access in real time. And so what that means is, is oftentimes you enroll a study and at the end of the study you identify the patient population that you had is perhaps younger, perhaps the patient population that you have is very homogeneous. But what our platform is able to do for patients with multiple myeloma and across diseases is to be able to see the type of patients that you’re enrolling into clinical trials in real time. And so that at any given time and point, you can access the platform, and then you can see the age of the patient population that you’re enrolling into a clinical trial. You can see race, ethnicity, gender, and then geographically where the patient is coming from. And so what this allows for providers or physicians who are enrolling into clinical trials is to get a sense of the type of patient and also to identify gaps in real time. And that’s the most important aspect of the age gauge platform is that it allows this real-time data capture and it’s all the data is presented in an aggregate. So there’s no protected health information, you can just see general numbers of who’s enrolling into a study. And it empowers physicians and teams to make sure that they’re approaching patients broadly. So one of the early signals that we presented here is looking at identifying areas geographically within the state so we can identify where we’re reaching. There are different community oncology centers throughout the state. And so we can identify whether or not patients that we’re enrolling into our trials are coming from certain parts of the state. And that’s important because we can reach out to those providers, provide education about the type of studies that we’re having, and to say, oh, we’re not getting a whole lot of patients from this area. And myeloma is kind of evenly distributed throughout the state. And so it provides an opportunity for us to have partnerships and also gives us a better sense of the type of patients we’re enrolling.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.